Abstract: The invention relates to a liquid recovery system for a motor vehicle where such a recovery system includes at least one liquid intake that communicates with a tank, which is designed to store liquid from the liquid intake, and is designed with an arrangement below the motor vehicle's beltline.

Abstract: Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers of PN and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).

Abstract: The invention relates to a liquid recovery system for a motor vehicle and to a vehicle including such a recovery system that that includes at least one liquid intake that communicates with a tank and is referred to as the first tank, which is designed to store liquid from the liquid intake and where the liquid intake is arrangeably designed below the vehicle's beltline.

Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

Abstract: Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers of PN and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).

Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding. The invention also provides bispecific antibodies that have CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding. The invention also concerns bispecific antibodies which are heterodimers of two IgG heavy chains that differ by at least two amino acids that allow for rapid isolation based on a differential affinity of one mutated heavy chain and a second mutated heavy chain toward two different affinity reagents.

Abstract: The invention relates to a telescopic cleaning device intended to spray at least a first fluid and at least a second fluid toward an exterior surface of a motor vehicle's sensor/emitter, the telescopic cleaning device including at least a first distribution orifice for a first fluid and at least a second distribution orifice for a second fluid, the telescopic cleaning device being configured to deploy along a deployment (D) axis where the first distribution orifice and the second distribution orifice are offset from one another along the cleaning device's axis of deployment (D).

Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: The invention relates to a liquid recovery system for a motor vehicle and to a vehicle including such a recovery system that that includes at least one liquid intake that communicates with a tank and is referred to as the first tank, which is designed to store liquid from the liquid intake and where the liquid intake is arrangeably designed below the vehicle's beltline.

Abstract: The invention concerns a rear view system (1) of a motor vehicle comprising:—an optical image capturing sensor (3),—a protective support (5) comprising a transparent and flat protective screen (7), the optical sensor (3) being installed on the protective support (5) in such a way as to point through said protective screen (7), and—a scraper blade (9) for cleaning the protective screen (7) disposed on the face of the protective screen (7) opposite that of the optical sensor (3) side, characterised in that it further comprises an electromagnetic actuation device (11) for actuating said scraper blade (9) in translation on the protective screen (7).

Abstract: The present invention relates to a new class of TNFR agonist comprising multiple binding portions to two different parts of the same TNFR. The present invention also relates to methods of activating components of the immune system in a patient via the administration of a TNFR agonist according to the present invention as well as the use of such materials for further therapeutic and other purposes.

Abstract: The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).

Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: The subject matter of the present invention is a module (5) for cleaning an optical element protection device (3) intended to equip a motor vehicle, said protection device (3) having a surface of revolution configured to be arranged around the optical element. The cleaning module (5) includes at least one ring (51) configured to surround the protection device (3) and includes at least one wiping structure. The ring (51) is configured to be mobile in relative movement in translation along an axis of revolution (A2) of the ring (51) relative to the protection device (3) such that said at least one wiping structure (53) of the ring (51) is configured to wipe the surface of revolution of the protection device (3).

Abstract: The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).

Abstract: The invention relates to an actuation device for a driving arm (2) of a wiper (3), in particular for a motor vehicle, said device comprising: a body (10) hinged to rotate about a pivot axis and capable of receiving the arm (2), and a means (14) for locking the arm (2) on the body (10), said locking means (14) being hinged with the body (10). The invention also relates to a system for wiping a window of a vehicle, comprising said device.

Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.